ArticleBone & joint open2026
Multicentre outcomes of total hip arthroplasty using a novel collared cementless femoral stem.
Article in Bone & joint open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Recent years have seen increased interest in tissue-sparing approaches for total hip arthroplasty (THA), which has led to innovations in implant design. Short cementless femoral components have gained traction, and the inclusion of a medial calcar collar to improve stability may offset the risk of fracture. The aim of this current study is to report short-term outcomes and survivorship for a novel design of femoral component across four non-designer centres. Methods: All patients undergoing primary THA across four centres from July 2020 to January 2025 were eligible for inclusion. Data were collected prospectively in a national arthroplasty register, with planned routine follow-up at six months and two years. Patient-reported outcome measures were assessed using the Oxford Hip Score (OHS) and EuroQol five-dimension questionnaire (EQ-5D) score. Results: A total of 517 components in 489 patients were included in the dataset: three patients (0.6%) died by final follow-up, and of the remaining 514 components, 512 components (99.6%) remain in situ. For the two patients (0.4%) undergoing revision surgery, indications for revision were periprosthetic fracture (PPF) and large postoperative haematoma. PPF affected four patients (0.8%) in total: two intraoperative events were managed with cables, and one Vancouver C fracture was managed with plate and screw fixation. The mean preoperative OHS was 17 (95% CI 16.3 to 17.7) with a mean postoperative score of 40.7 (95% CI 39.7 to 41.5), and mean preoperative EQ-5D score was 0.36 (95% CI 0.34 to 0.38), with a mean postoperative score of 0.80 (95% CI 0.78 to 0.82). Conclusion: This novel femoral component demonstrates excellent functional outcomes which are reproducible across multiple surgeons in non-designer centres, with low rates of revision surgery and PPF.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.